OncoMatch/Clinical Trials/NCT06170489
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Is NCT06170489 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including JS004 in combination with Toripalimab and Bendamustine or gemcitabine for hodgkin lymphoma.
Treatment: JS004 in combination with Toripalimab · Bendamustine or gemcitabine — The study is being conducted to compare JS004 plus Toripalimab with Investigator-Selected Chemotherapy in Patients with PD-(L)1 monoclonal antibody refractory Classic Hodgkin Lymphoma (cHL)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: PD-(L)1 monoclonal antibody
refractory to PD-(L)1 monoclonal antibody (mAb)
Must have received: standard treatment
Has exhausted all standard treatment
Cannot have received: anti-PD-(L)1 antibody
Exception: permanent discontinuation due to immune-related adverse reactions
Permanent discontinuation of anti-PD-(L)1 antibody due to immune-related adverse reactions.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06170489 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-(L)1 antibody disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages